What Analysts Recommend for Stryker after 1Q17 Results



Analysts’ recommendations

Let’s look at Wall Street analysts’ recommendations and target prices for Stryker (SYK) over the next 12 months. In a Reuters survey of 26 brokerage companies on April 26, 2017, about 65.4% of analysts rated it as a “buy,” and 23.1% rated it as a “hold.” Around 11.5% of analysts rated it as a “sell.”

The table above provides a recommendation summary for Stryker over the next year. The consensus 12-month target price for Stryker is $141, a ~3.5% return potential. Stryker was trading at $136.2 on April 26, 2017.

According to analysts’ most recent recommendations, the lowest one-year target price for Stryker was $120, implying a -12% return potential over the next 12 months. On the other hand, Stryker’s highest one-year target price was $148, implying a ~8.7% return potential over the next 12 months.

Peers Thermo Fisher Scientific (TMO), Medtronic (MDT), and Zimmer Biomet (ZBH) have average broker target prices of $182.2, $87.8, and $134.1, respectively. These figures imply returns of 9.3%, 5.7%, and 13.5%, respectively, in the next 12 months. 

Article continues below advertisement

ETFs with exposure to Stryker

Investors interested in gaining focused exposure to Stryker can consider investing in the iShares U.S. Medical Devices ETF (IHI). IHI has 5.5% of its total holdings in Stryker. IHI tracks the Dow Jones U.S. Select Medical Equipment Index. It is one of the largest US medical device ETFs.

You may want to consider investing in dividend ETFs such as the Vanguard Dividend Appreciation ETF (VIG). VIG tracks the NASDAQ US Dividend Achievers Select Index, a market-cap-weighted index consisting of US companies that have paid their shareholders increasing dividends for at least ten consecutive years. VIG has ~1.4% of its total holdings in Stryker.


More From Market Realist